Trial Profile
International, Multicentre, Parallel-group, Randomised, Double-blind, Placebo-controlled, Phase III Study Evaluating the Effect of Dapagliflozin on Exercise Capacity in Heart Failure Patients With Reduced Ejection Fraction
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Dec 2023
Price :
$35
*
At a glance
- Drugs Dapagliflozin (Primary)
- Indications Chronic heart failure
- Focus Registrational; Therapeutic Use
- Acronyms DETERMINE-Reduced
- Sponsors AstraZeneca; AstraZeneca AB
- 07 Dec 2023 Results from NCT03877237 and NCT03877224 assessing Effect of Dapagliflozin Versus Placebo on Symptoms and 6-Minute Walk Distance in Patients With Heart Failure, published in the Circulation
- 19 Mar 2020 Status changed from active, no longer recruiting to completed.
- 12 Nov 2019 Planned End Date changed from 31 Jan 2020 to 26 Feb 2020.